NCT02134899View on ClinicalTrials.gov

The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 14, 2014

Primary Completion Date

November 11, 2017

Study Completion Date

November 11, 2017

Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
DRUG

Everolimus

Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression

DRUG

Calcineurin inhibitors maintenance

Usual treatment

Trial Locations (1)

94275

Bicêtre Hospital, Le Kremlin-Bicêtre

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02134899 - The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients | Biotech Hunter | Biotech Hunter